Ascentage Pharma Group International (AAPG) Releases Q4 2025 Earnings: Revenue Up 162% but Net Loss Narrows

Ascentage Pharma Group International (AAPG) reported Q4 2025 results with total revenue of $24.7 million, up 162.15% year-over-year, and gross profit of $22.7 million, up 164.53% year-over-year.

Cost of sales: $2.0 million (+137.67% YoY).

Operating result: operating loss of -$50.4 million (improved 56.24% YoY).

Net result attributable to common shareholders: net loss of -$47.6 million (improved 22.05% YoY).

Diluted earnings per share: -$0.52 per share (flat year-over-year).

The company held a strong liquidity position with cash and cash equivalents of $353.1 million, an increase of 104.32% versus the prior year, while total liabilities rose to $375.8 million (+17.05% YoY).

Cash from operating activities: -$30.2 million (down 279.99% YoY).

Purchases of property, plant and equipment: -$0.6 million (+8.58% YoY).

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Ascentage Pharma Group International Hedge Fund Activity

We have seen 5 institutional investors add shares of Ascentage Pharma Group International stock to their portfolio, and 9 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

POINT72 ASSET MANAGEMENT, L.P. added 16,726 shares (+inf%) to their portfolio in Q4 2025, for an estimated $438,890
UBS GROUP AG removed 14,113 shares (-76.9%) from their portfolio in Q4 2025, for an estimated $370,325
TEMA ETFS LLC removed 10,385 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $272,502
NEOS INVESTMENT MANAGEMENT LLC removed 10,385 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $272,502
ABC ARBITRAGE SA removed 5,230 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $137,235
XY CAPITAL LTD removed 4,492 shares (-24.8%) from their portfolio in Q4 2025, for an estimated $117,870
TOWER RESEARCH CAPITAL LLC (TRC) removed 599 shares (-72.3%) from their portfolio in Q4 2025, for an estimated $15,717

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Ascentage Pharma Group International Analyst Ratings

Wall Street analysts have issued reports on $AAPG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 03/26/2026
Truist Securities issued a "Buy" rating on 11/24/2025

To track analyst ratings and price targets for Ascentage Pharma Group International, check out Quiver Quantitative's $AAPG forecast page.

Ascentage Pharma Group International Price Targets

Multiple analysts have issued price targets for $AAPG recently. We have seen 5 analysts offer price targets for $AAPG in the last 6 months, with a median target of $48.0.

Here are some recent targets:

Jeet Mukherjee from BTIG set a target price of $48.0 on 04/13/2026
Matthew Biegler from Oppenheimer set a target price of $45.0 on 12/04/2025
Gregory Renza from Truist Securities set a target price of $51.0 on 11/24/2025
Biren Amin from Piper Sandler set a target price of $48.0 on 11/05/2025